Cost Effectiveness Analysis of Dimethyl Fumarate Versus Teriflunomide for The Treatment of Multiple Sclerosis

L Ruiz; M Machado; H Toro-Diaz; C Cele; L Hernandez; A Harrington

doi:10.1016/j.jval.2017.08.1952

Cost Effectiveness Analysis of Dimethyl Fumarate Versus Teriflunomide for The Treatment of Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2017.08.1952 ◽

2017 ◽

Vol 20 (9) ◽

pp. A724

Author(s):

L Ruiz ◽

M Machado ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2598 ◽

2015 ◽

Vol 18 (7) ◽

pp. A697 ◽

Cited By ~ 4

Author(s):

G Furneri ◽

L Santoni ◽

C Marchesi ◽

S Iannazzo ◽

P Cortesi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2019.09.1794 ◽

2019 ◽

Vol 22 ◽

pp. S740-S741

Author(s):

L.G. Mantovani ◽

G. Furneri ◽

P.A. Cortesi ◽

E. Puma ◽

L. Santoni ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2015.09.2931 ◽

2015 ◽

Vol 18 (7) ◽

pp. A755 ◽

Cited By ~ 1

Author(s):

D Gasche ◽

G Restovic ◽

V Casado ◽

P Ramírez-Boix ◽

J Martínez Lopez

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis

The Lancet Neurology ◽

10.1016/s1474-4422(19)30190-5 ◽

2019 ◽

Vol 18 (8) ◽

pp. 736-747 ◽

Cited By ~ 9

Author(s):

Jennifer Freeman ◽

Wendy Hendrie ◽

Louise Jarrett ◽

Annie Hawton ◽

Andrew Barton ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Progressive Multiple Sclerosis ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Home Based ◽

Randomised Controlled

Download Full-text

Cost-Effectiveness Analysis of Cladribine Tablets for Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in Bulgaria

Value in Health ◽

10.1016/j.jval.2018.04.1403 ◽

2018 ◽

Vol 21 ◽

pp. S206 ◽

Cited By ~ 1

Author(s):

S Djambazov ◽

G Slavchev ◽

T Dineva ◽

P Panayotov ◽

T Vekov

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND66 - COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN CYPRUS

Value in Health ◽

10.1016/j.jval.2018.09.2032 ◽

2018 ◽

Vol 21 ◽

pp. S340

Author(s):

N Kourkoulas ◽

K Athanasakis ◽

M Theodorou ◽

J Kyriopoulos

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Treatment Option ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

BMC Health Services Research ◽

10.1186/s12913-019-4264-1 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 1

Author(s):

Gianluca Furneri ◽

Laura Santoni ◽

Chiara Ricella ◽

Luca Prosperini

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Alternative Therapies in non-primary progressive Multiple Sclerosis

Research in Social and Administrative Pharmacy ◽

10.1016/j.sapharm.2010.09.006 ◽

2011 ◽

Vol 7 (1) ◽

pp. e1

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Progressive Multiple Sclerosis ◽

Cost Effectiveness Analysis ◽

Alternative Therapies ◽

Primary Progressive Multiple Sclerosis ◽

Primary Progressive ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

Journal of Medical Economics ◽

10.3111/13696998.2012.654868 ◽

2012 ◽

Vol 15 (3) ◽

pp. 424-433 ◽

Cited By ~ 15

Author(s):

Rainel Sánchez-de la Rosa ◽

Eliazar Sabater ◽

Miguel Angel Casado ◽

Rafael Arroyo

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Multiple Sclerosis Patients ◽

Relapsing Multiple Sclerosis

Download Full-text

PNL9 COST EFFECTIVENESS ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)

Value in Health ◽

10.1016/s1098-3015(10)62282-6 ◽

2004 ◽

Vol 7 (3) ◽

pp. 290

Author(s):

M Iskedjian ◽

J Walker ◽

T Gray ◽

C Vicente ◽

T Einarson ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Definite Multiple Sclerosis ◽

Clinically Definite Multiple Sclerosis

Download Full-text